Plant Name: Heracleum sphondylium
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: |
|---|
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 2.744E-11 | 5.976E-07 | CYP1A2, CYP2C19, CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0008202; steroid metabolic process | 3.934E-10 | 2.807E-06 | AKR1B10, CYP1A2, CYP2A6, CYP2C19, CYP2D6, CYP3A4, HSD11B1, NR1H4 |
| MF | GO:0003824; catalytic activity | GO:0008395; steroid hydroxylase activity | 5.157E-10 | 2.807E-06 | CYP2A13, CYP2A6, CYP2C19, CYP2D6, CYP3A4 |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 9.011E-10 | 3.924E-06 | CYP1A2, CYP2A6, CYP2C19, CYP3A4 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 2.244E-09 | 6.980E-06 | CYP1A2, CYP2A13, CYP2C19, CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0006805; xenobiotic metabolic process | 4.567E-09 | 9.945E-06 | CYP1A2, CYP2A13, CYP2C19, CYP2D6, CYP3A4, RORC |
| MF | GO:0005488; binding | GO:0020037; heme binding | 9.185E-09 | 1.667E-05 | CYP1A2, CYP2A13, CYP2A6, CYP2C19, CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 1.081E-08 | 1.811E-05 | CYP1A2, CYP2A13, CYP2A6, CYP2C19 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 1.597E-08 | 2.319E-05 | CYP1A2, CYP2A13, CYP2D6, CYP3A4 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 3.498E-08 | 4.232E-05 | CYP1A2, CYP2A13, CYP2A6, CYP2C19, CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0009804; coumarin metabolic process | 5.879E-08 | 5.566E-05 | CYP2A13, CYP2A6, CYP2D6 |
| BP | GO:0008152; metabolic process | GO:0035335; peptidyl-tyrosine dephosphorylation | 1.257E-07 | 1.013E-04 | ACP1, CDC25B, PTPN1, PTPN2, PTPRF |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 3.681E-07 | 2.290E-04 | CYP1A2, CYP2D6, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0008392; arachidonic acid epoxygenase activity | 1.133E-06 | 6.168E-04 | CYP2A13, CYP2A6, CYP2C19 |
| MF | GO:0003824; catalytic activity | GO:0008389; coumarin 7-hydroxylase activity | 1.480E-06 | 7.492E-04 | CYP2A13, CYP2A6 |
| BP | GO:0008152; metabolic process | GO:0009822; alkaloid catabolic process | 4.435E-06 | 1.876E-03 | CYP2D6, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0038183; bile acid signaling pathway | 4.435E-06 | 1.876E-03 | GPBAR1, NR1H4 |
| MF | GO:0060089; molecular transducer activity | GO:0038181; bile acid receptor activity | 4.435E-06 | 1.876E-03 | GPBAR1, NR1H4 |
| BP | GO:0009987; cellular process | GO:1902202; regulation of hepatocyte growth factor receptor signaling pathway | 8.864E-06 | 3.447E-03 | PTPN1, PTPN2 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 8.864E-06 | 3.447E-03 | CYP1A2, CYP3A4 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 2.449E-10 | 3.282E-08 | HSD11B1; CYP2A6; CYP2A13; CYP2D6; CYP1A2; CYP3A4 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 5.003E-10 | 3.352E-08 | HSD11B1; CYP2A6; CYP2A13; CYP1A2; CYP3A4; CYP2C19 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 1.704E-08 | 7.609E-07 | CYP2A6; CYP2D6; CYP1A2; CYP3A4; CYP2C19 |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 7.071E-07 | 1.895E-05 | HSD11B1; CYP2A6; AKR1B10; PLA2G1B; GAA; CYP1A2; ALPL; CYP2C19; CYP3A4; HSD17B10 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 3.712E-08 | 1.243E-06 | PLA2G1B; CYP1A2; CYP3A4; CYP2C19 |
| hsa04520 | Adherens junction_Homo sapiens_hsa04520 | 1.735E-06 | 3.874E-05 | PTPN1; MAPK1; ACP1; PTPRF |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 6.316E-05 | 9.403E-04 | CYP2A6; CYP1A2; CYP3A4 |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 4.486E-05 | 7.514E-04 | HSD11B1; CYP1A2; CYP3A4 |
| hsa04931 | Insulin resistance_Homo sapiens_hsa04931 | 2.932E-04 | 3.869E-03 | PTPN1; NFKB1; PTPRF |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 3.176E-04 | 3.869E-03 | CYP2D6; MAPK1; CYP2C19 |
| hsa04910 | Insulin signaling pathway_Homo sapiens_hsa04910 | 5.975E-04 | 6.158E-03 | PTPN1; MAPK1; PTPRF |
| hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 1.832E-03 | 1.637E-02 | POLB; MAPK1; NFKB1 |
| hsa04014 | Ras signaling pathway_Homo sapiens_hsa04014 | 2.449E-03 | 1.648E-02 | PLA2G1B; MAPK1; NFKB1 |
| hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 2.116E-03 | 1.648E-02 | MAPK1; NFKB1 |
| hsa00983 | Drug metabolism - other enzymes_Homo sapiens_hsa00983 | 1.383E-03 | 1.324E-02 | CYP2A6; CYP3A4 |
| hsa04010 | MAPK signaling pathway_Homo sapiens_hsa04010 | 3.401E-03 | 1.648E-02 | MAPK1; NFKB1; CDC25B |
| hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 5.881E-04 | 6.158E-03 | AKR1B10; GAA |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 2.497E-03 | 1.648E-02 | PLA2G1B; CYP2C19 |
| hsa04621 | NOD-like receptor signaling pathway_Homo sapiens_hsa04621 | 2.116E-03 | 1.648E-02 | MAPK1; NFKB1 |
| hsa05321 | Inflammatory bowel disease (IBD)_Homo sapiens_hsa05321 | 2.741E-03 | 1.648E-02 | RORC; NFKB1 |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 2.825E-03 | 1.648E-02 | MAPK1; NFKB1 |
| hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 3.351E-03 | 1.648E-02 | MAPK1; NFKB1 |
| hsa04662 | B cell receptor signaling pathway_Homo sapiens_hsa04662 | 3.443E-03 | 1.648E-02 | MAPK1; NFKB1 |
| hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 5.208E-03 | 2.181E-02 | MAPK1; NFKB1; CDC25B |
| hsa05131 | Shigellosis_Homo sapiens_hsa05131 | 2.741E-03 | 1.648E-02 | MAPK1; NFKB1 |
| hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 3.443E-03 | 1.648E-02 | MAPK1; NFKB1 |
| hsa05140 | Leishmaniasis_Homo sapiens_hsa05140 | 3.443E-03 | 1.648E-02 | MAPK1; NFKB1 |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 3.260E-03 | 1.648E-02 | NR1H4; CYP3A4 |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 5.071E-03 | 2.181E-02 | MAPK1; NFKB1 |
| hsa04933 | AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | 6.482E-03 | 2.484E-02 | MAPK1; NFKB1 |
| hsa04914 | Progesterone-mediated oocyte maturation_Homo sapiens_hsa04914 | 6.114E-03 | 2.483E-02 | MAPK1; CDC25B |
| hsa05133 | Pertussis_Homo sapiens_hsa05133 | 3.630E-03 | 1.677E-02 | MAPK1; NFKB1 |
| hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 6.733E-03 | 2.484E-02 | MAPK1; NFKB1 |
| hsa05132 | Salmonella infection_Homo sapiens_hsa05132 | 4.743E-03 | 2.119E-02 | MAPK1; NFKB1 |
| hsa04660 | T cell receptor signaling pathway_Homo sapiens_hsa04660 | 6.860E-03 | 2.484E-02 | MAPK1; NFKB1 |
| hsa04620 | Toll-like receptor signaling pathway_Homo sapiens_hsa04620 | 7.117E-03 | 2.510E-02 | MAPK1; NFKB1 |
| hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 7.645E-03 | 2.627E-02 | MAPK1; NFKB1 |
| hsa05142 | Chagas disease (American trypanosomiasis)_Homo sapiens_hsa05142 | 6.860E-03 | 2.484E-02 | MAPK1; NFKB1 |
| hsa05145 | Toxoplasmosis_Homo sapiens_hsa05145 | 8.752E-03 | 2.817E-02 | MAPK1; NFKB1 |
| hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 9.039E-03 | 2.817E-02 | MAPK1; NFKB1 |
| hsa04270 | Vascular smooth muscle contraction_Homo sapiens_hsa04270 | 9.039E-03 | 2.817E-02 | PLA2G1B; MAPK1 |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 1.214E-02 | 3.536E-02 | MAPK1; NFKB1 |
| hsa04380 | Osteoclast differentiation_Homo sapiens_hsa04380 | 1.085E-02 | 3.278E-02 | MAPK1; NFKB1 |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 1.315E-02 | 3.749E-02 | MAPK1; NFKB1 |
| hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 9.039E-03 | 2.817E-02 | MAPK1; NFKB1 |
| hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 1.101E-02 | 3.278E-02 | MAPK1; NFKB1 |
| hsa05164 | Influenza A_Homo sapiens_hsa05164 | 1.852E-02 | 4.963E-02 | MAPK1; NFKB1 |
| hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 1.715E-02 | 4.690E-02 | MAPK1; HSD17B10 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 1.377E-05 | 2.636E-04 | CYP2A6; CYP1A2 |
| hsa00790 | Folate biosynthesis_Homo sapiens_hsa00790 | 1.667E-02 | 4.655E-02 | ALPL |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | PTPN1; PTPN1; GPBAR1; HSD11B1; NFKB1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CYP2D6 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of corticosteroid responsive dermatoses | L20-L30 | PLA2G1B |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | PLA2G1B |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic syndrome x | E88.81 | HSD11B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | GPBAR1; HSD11B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | PTPN1; HSD11B1; HSD11B1 |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | CYP2D6 |
| J00-J99: Diseases of the respiratory system | Influenza virus | J11.1 | HSD11B1 |
| C00-D49: Neoplasms | Cancer | C00-C96 | MAPK1; NFKB1; CDC25B |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | HSD11B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Lipid metabolism disorder | E75-E78 | HSD11B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypercholesterolemia | E78 | HSD11B1 |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | CYP2D6 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses of the scalp | L20-L30 | PLA2G1B |
| L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | PLA2G1B |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Nerve injury | T14.4 | PLA2G1B |
| A00-B99: Certain infectious and parasitic diseases | Anthelmintic | B89 | ALPL |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | PLA2G1B |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | PTPN1; HSD11B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | HSD11B1 |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | PLA2G1B |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | PLA2G1B |
| A00-B99: Certain infectious and parasitic diseases | Infections | A00-B99 | PTPN1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | PLA2G1B |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | MAPK1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Contact dermatitis | L23, L24, L25 | PLA2G1B |
| NA: NA | Colour dead tissues | NA | PTPN1 |
| C00-D49: Neoplasms | Colon cancer | C50 | ALPL |
| A00-B99: Certain infectious and parasitic diseases | Visceral leishmaniasis | B55.0 | PLA2G1B |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1 |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | HSD11B1 |
| I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | PLA2G1B |
| E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | GAA |
| A00-B99: Certain infectious and parasitic diseases | Leishmaniasis | B55.0 | PLA2G1B |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Genetic disease | Q00-Q99 | ALPL |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | PLA2G1B |